Nonadherence to Primary Prophylaxis against Pneumocystis jirovecii Pneumonia

被引:7
|
作者
Heffelfinger, James D. [1 ]
Voetsch, Andrew C. [1 ]
Nakamura, Glenn V. [1 ]
Sullivan, Patrick S. [2 ]
McNaghten, A. D. [1 ]
Huang, Laurence [3 ,4 ]
机构
[1] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA
[2] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA
[3] Univ Calif San Francisco, HIV AIDS Div, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Div Pulmonary & Critical Care Med, San Francisco, CA 94143 USA
来源
PLOS ONE | 2009年 / 4卷 / 03期
基金
美国国家卫生研究院;
关键词
ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; CARINII PNEUMONIA; UNITED-STATES; DRUG-USE; ADHERENCE; PATIENT; EPIDEMIOLOGY; BIAS; AIDS;
D O I
10.1371/journal.pone.0005002
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Despite the effectiveness of prophylaxis, Pneumocystis jirovecii pneumonia (PCP) continues to be the most common serious opportunistic infection among HIV-infected persons. We describe factors associated with nonadherence to primary PCP prophylaxis. Methodology/Principal Findings: We used 2000-2004 data from the Supplement to HIV/AIDS Surveillance (SHAS) project, a cross-sectional interview project of HIV-infected persons >= 18 years conducted in 18 states. We limited the analysis to persons who denied having prior PCP, reported having a current prescription to prevent PCP, and answered the question "In the past 30 days, how often were you able to take the PCP medication(s) exactly the way your doctor told you to take them?'' We used multivariable logistic regression to describe factors associated with nonadherence. Of 1,666 subjects prescribed PCP prophylaxis, 305 (18.3%) were nonadherent. Persons were more likely to be nonadherent if they reported using marijuana (adjusted odds ratio [aOR] = 1.6, 95% confidence interval [CI] = 1.1-2.4), non-injection drugs other than marijuana (aOR = 1.5, 95% CI = 1.0-2.1), or injection drugs (aOR = 2.3, 95% CI = 1.3-4.1) in the past year; their mental health was "not good'' for >= 1 day during the past month (aOR = 1.6, 95% CI = 1.2-2.2); their most recent CD4 count was,200 cells/mu L (aOR = 1.6, 95% CI = 1.1-2.2); or taking ART usually (aOR = 9.6, 95% CI = 6.7-13.7) or sometimes/rarely/never (aOR = 18.4, 95% CI = 11.1-30.4), compared with always, as prescribed. Conclusion/Significance: Providers should inquire about and promote strategies to improve adherence to PCP prophylaxis, particularly among persons who use illicit drugs, have mental health issues, and who are not compliant with ART to reduce the occurrence of PCP.
引用
下载
收藏
页数:7
相关论文
共 50 条
  • [31] Pneumocystis jirovecii Pneumonia in Children
    Dhingra, Dhulika
    Mandal, Anirban
    Singh, Amitabh
    JOURNAL OF PEDIATRIC INFECTIOUS DISEASES, 2018, 13 (01) : 2 - 9
  • [32] Diagnosis of Pneumocystis jirovecii pneumonia
    Alanio, A.
    MYCOSES, 2017, 60 : 30 - 30
  • [33] Pneumocystis Jirovecii Prophylaxis in Neurosurgery
    de Lotbiniere-Bassett, Madeleine
    Dhillon, Mannat
    Couillard, Philippe
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2021, 48 (04) : 592 - 593
  • [34] Cavitary Pneumocystis jirovecii pneumonia
    MacCann, R.
    O'Brien, C.
    McCarthy, C.
    Dodd, J. D.
    Fabre, A.
    Feeney, E. R.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2021, 114 (08) : 607 - 608
  • [35] Prophylaxis Against Pneumocystis Pneumonia-Reply
    Zhou, Shiwei
    Aitken, Samuel L.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 330 (19): : 1909 - 1909
  • [36] PROPHYLAXIS AGAINST PNEUMOCYSTIS-CARINII PNEUMONIA
    GABIN, SJ
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (13): : 1779 - 1779
  • [37] Withdrawal of prophylaxis against Pneumocystis carinii pneumonia
    Feinberg, J
    LANCET, 1999, 353 (9161): : 1287 - 1287
  • [38] Letter: time to consider Pneumocystis jirovecii pneumonia prophylaxis in treatment of autoimmune hepatitis
    Schneider, Daniel
    Strathmore, Alexander
    Yu, Catherine
    Hannah, Nicholas
    Sood, Siddharth
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 57 (10) : 1210 - 1211
  • [39] PNEUMOCYSTIS JIROVECII PNEUMONIA IN HOSPITALIZED CANCER PATIENTS: INCIDENCE, RISK FACTORS, AND PROPHYLAXIS
    Van Hook, Reed
    Mantha, Aditya
    Rhoads, Sarah L.
    Spradlin, Megan
    Pons, Shelby
    Mccollister, Bruce
    Mueller, Scott
    Kannappan, Arun
    Maloney, James P.
    CHEST, 2023, 164 (04) : 801A - 802A
  • [40] Acute generalised exanthematous pustulosis induced by Pneumocystis jirovecii pneumonia prophylaxis with dapsone
    Vas, A.
    Laws, P.
    Marsland, A. M.
    McQuillan, O.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2013, 24 (09) : 745 - 747